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Abstract Dihydropyrimidine dehydrogenase catalyzes the 
first and rate-limiting step in the breakdown of thymine, 
uracil, and the widely used antineoplastic drug, 5-fluo- 
rouracil. Sequence analysis of the dihydropyrimidine de­
hydrogenase cDNA in a Dutch consanguineous family 
identified a novel four-base deletion (delTCAT296_299) lead­
ing to premature termination of translation. The deletion 
is located in a TCAT tandem-repeat sequence and most 
likely results from unequal crossing-over or slipped mis- 
pairing. In this family we identified three homozygous in­
dividuals for this mutation. Two of these showed convul­
sive disorders but one was clinically normal This obser­
vation suggests that, at least in this family, there is no 
clear correlation between the dihydropyrimidine dehydro­
genase genotype and phenotype.
Introduction
Dihydropyrimidine dehydrogenase (DPD) deficiency 
(McKusick 274270) is a clinically heterogeneous, autoso­
mal recessive disease (Berger et al. 1984; Braakhekke et 
al. 1987; Van Gennip et al. 1987, 1989, 1994). DPD (EC
1.3.1.2) catalyzes the first and rate-limiting step in the ca­
tabolism of uracil, thymine, and the thymin analog, 5-flu- 
orouracil (Lu et al. 1993). Patients with a nearly complete 
enzyme defect show convulsive disorders in about 50% of 
cases, whereas patients experiencing acute 5-fluorouracil 
toxicity usually show DPD enzymatic activities in the het­
erozygous range. Recently, it was demonstrated that such 
patients are indeed heterozygous for a genomic DPD mu-
P. Vreken (E3) • A. B. P. Van Kuilenburg • R. Meinsma 
A. H. Van Gennip
Academic Medical Center, University of Amsterdam, 
Departments of Pediatrics and Clinical Chemistry F0-224, 
P.O. Box 22700, NL-1100 DH Amsterdam, The Netherlands 
Fax: +31 206962596; e-mail: p.vreken@amc.uva.nl
R. A. De Abreu
Academic Hospital Nijmegen, Department of Pediatrics,
P.O. Box 9101, NL-6500 HB Nijmegen, The Netherlands
tation (Wei et al. 1996; A. B. P. Kuilenburg et al. unpub­
lished results).
The human DPD enzyme consists of two identical sub­
units of 111 kDa and is encoded by a single gene mapped 
to chromosome lp22 (Takai et al. 1.994; Yokota et al. 
1994). The recent cloning o f the DPD cDNA and a small 
part of the genomic DPD gene now allows detection of 
the defect at the molecular level (Yokota et al. 1994; 
Vreken et al. 1996 a). So far, three mutations in the DPD 
gene have been described. The first mutation is a G—»A 
point mutation in an invariant GT splice donor sequence 
leading to skipping of the 165-bp exon immediately up­
stream of the splice donor site mutation (Meinsma et al. 
1995; Vreken et al. 1996a). This mutation has been iden­
tified in 7 out of 12 patients with complete DPD defi­
ciency in either the homozygous or heterozygous state 
and has an apparently high frequency among DPD-defi- 
cient individuals from northern Europe (Vreken et al. 
1996 a, b). In addition, this mutation was indentified in 
patients experiencing acute 5-fluorouracil toxicity (Wei et 
al. 1996; A. B. P. Van Kuilenburg et al., unpublished re­
sults). Two other mutations, a frameshift (AC 1897) and a 
missense (C29R) mutation, were identified in two patients 
from Turkey (Vreken et al. 1996 b, 1997).
We now report a novel four-base deletion (delT- 
CAT296-299) in a family with DPD deficiency.
Materials and methods
Patients
The family investigated in this study has been extensively de-
«
scribed elsewhere (Braakhekke et al. 1987). Briefly, the propositus 
(patient A) was diagnosed having thymine-uraciluria at the age of
4 years. Clinically she showed epileptic manifestations and micro­
cephaly. She is the second child of consanguineous Dutch parents. 
In addition, her mother is the child of a consanguineous relation­
ship, her father is also her grandfather. From the age of 19 years, 
the mother suffered from generalized tonic seizures. The brother 
and father of the propositus are clinically normal. In the previous 
study, the propositus, her mother, and brother were shown to be 
homozygous DPD deficient as judged by enzymatic measurements 
of the DPD activity in fibroblasts of these patients. The father of
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DPD protein cannot express any residual activity, in ac­
cordance with the undetectable levels of DPD activity in 
fibroblasts from the homozygous individuals studied here 
(Braakhekke et al. 1987).
The delTCAT296_299 mutation is part of a TCAT tan­
dem repeat, Repeat sequences are often involved in DNA  
rearrangements (Chandley 1989). Either slipped mispair- 
ing or unequal chromosome crossing-over were suggested 
to be the likely mechanisms for the generation of such
mutations (Efstratiadis et al. 1980; Smith 1976).
Patient A, her mother, and her brother show the same 
DPD genotype and all three lack any DPD enzymatic ac­
tivity. However, patient A showed epileptic manifesta­
tions and microcephaly and her mother suffers from gen­
eralized tonic seizures, whereas the brother of the patient 
is clinically normal. The lack of correlation between 
genotype and phenotype in this family cannot easily be 
explained. However, both population screening based on 
DPD catalytic activity and a limited screening study for 
the common splice donor site mutation releaved thas as 
much as 3—5% of the normal population could be hetero­
zygotes for mutant DPD alleles (Lu et al. 1993; McMur- 
rough and McLeod 1996; Wei et al. 1996). These studies 
suggest that up to 1 in every 1000 births in the general 
population might be homozygous for DPD mutations. 
These figures are at least 10-20 times higher than the ob­
served frequency for completely DPD-deficient patients, 
suggesting that either the vast majority of DPD-deficient 
individuals shows no clinical phenotype or that metabolic 
screening programs fail to detect these patients. Since, at 
least in the Netherlands, metabolic screening in pediatric 
patients with neurological symptoms always includes 
analysis of purines and pyrimidines, thus allowing the de­
tection of DPD deficiency, it is more likely that indeed a 
number of patients show no characteristic clinical pheno­
type. Apparently, additional factors must play in impor­
tant role in expression of the clinical phenotype. One of 
these factors might include (3-alanine homeostasis since 
this neurotransmitter cannot be synthesized and can only 
be derived from dietary sources in DPD- deficient indi­
viduals (Van Kuilenburg et al. 1996). The relationship be­
tween P-alanine homeostasis and clinical symptoms is 
currently under investigation in our laboratory.
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